According to the report, the research and development of new drugs usually takes more than ten years, which will occupy the validity period of patents in the process of clinical research, review and approval, and may expire in a few years after listing. At present, the drug trial reform puts forward to carry out the pilot of the compensation system for drug patent term, and suggests to establish a data protection system for drug trials suitable for the national conditions, so as to further solve the problem of insufficient patent term after new drugs are listed and better encourage innovation.
In addition, besides patent protection, clinical trials are also an important part of new drug research and development. The existing drug clinical trial institutions, experts and clinical management professionals in China are far from meeting the rapidly growing demand for clinical research of new drugs, and clinical research has become the bottleneck of new drug research and development and industrialization.
Analysts said that the drug trial reform is a systematic project, which needs the concerted action of the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Finance, the Health and Health Commission, Ministry of Human Resources and Social Security and other departments. Only in this way can we promote new drugs to enter the clinical drug list, bidding and purchasing, medical insurance reimbursement and other links in time, and truly let the people enjoy the dividend of reform.